Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Cited by (851)

Items 101–200 of 851

1. Lung cancer is also a hereditary disease
   Patrick R. Benusiglio, Vincent Fallet, Mateo Sanchis-Borja, Florence Coulet, Jacques L. Cadranel · 2021 · European Respiratory Review
2. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
   Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca J. Nagy, Richard Burnham Lanman, Michael F. Berger, David Michael Hyman, David B. Solit et al. · 2017 · Cancer Discovery
3. Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
   Adrian Gerold Sacher, Kimberly Mayumi Komatsubara, Geoffrey R. Oxnard · 2017 · Journal of Thoracic Oncology
4. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
   Perets, Ruth, Greenberg, Orli, Shentzer, Talia, Semenisty, Valeria, Epelbaum, Ron, Bick, Tova, Sarji, Shada, Ben-Izhak, Ofer, Sabo, Edmond, Hershkovitz, Dov · 2018 · The Oncologist
5. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
   Mei Yang, M. Elizabeth Forbes, Rhonda Lynn Bitting, Stacey S. O’Neill, P -C Chou, Ümit Topaloĝlu, Lance David Miller, Gregory A. Hawkins, Stefan C. Grant, Barry R. DeYoung et al. · 2017 · Annals of Oncology
6. Recommendations for Cell-Free DNA Assay Validations
   Lockwood, Christina M., Borsu, Laetitia, Cankovic, Milena, Earle, Jonathan S.L., Gocke, Christopher D., Hameed, Meera, Jordan, Danielle, Lopategui, Jean R., Pullambhatla, Mrudula, Reuther, Jacquelyn et al. · 2023 · The Journal of Molecular Diagnostics
7. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
   Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eléonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse et al. · 2017 · Clinical Lung Cancer
8. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
   Minji Lim, Chi‐Ju Kim, Vijaya Sunkara, Mi‐Hyun Kim, Yoon‐Kyoung Cho · 2018 · Micromachines
9. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
   Jonathan Andrew Ledermann, Éric Pujade-Lauraine · 2019 · Therapeutic Advances in Medical Oncology
10. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
    Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michèle Milella, Giampaolo Tortora et al. · 2020 · Cancers
11. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
    Mariacarmela Santarpía, Alessia Liguori, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla, Rafael Rosell · 2017 · Lung Cancer Targets and Therapy
12. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management
    Julie A. Vendrell, Frédéric Tran Mau‐Them, Benoît Béganton, Sylvain Godreuil, Peter J. Coopman, Jérôme Solassol · 2017 · International Journal of Molecular Sciences
13. Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients
    Florence de Fraipont, Sylvie Gazzéri, William Chi Shing Cho, Béatrice Eymin · 2019 · Frontiers in Genetics
14. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
    Francesco Passiglia, Sérgio Rizzo, Massimo Di Maïo, Antonio Galvano, Giuseppe Badalamenti, Angela Listì, Leonardo Gulotta, Marta Castiglia, Fabio Fulfaro, Viviana Bazan et al. · 2018 · Scientific Reports
15. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
    Ibiayi Dagogo‐Jack, Marguerite M. Rooney, Rebecca J. Nagy, Jessica J. Lin, Emily N. Chin, Lorin A. Ferris, Jennifer Ackil, Jochen K. Lennerz, Richard Burnham Lanman, Justin F. Gainor et al. · 2019 · Journal of Thoracic Oncology
16. The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
    Daniel Di Capua, Dara Mark Bracken-Clarke, Karine E. Ronan, Anne‐Marie Baird, Stephen P. Finn · 2021 · Cancers
17. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor
    Daniel Zaidman, Paul Gehrtz, Mihajlo Filep, D. Fearon, Ronen Gabizon, A. Douangamath, Jaime Prilusky, Shirly Duberstein, Galit Cohen, Callum D. Owen et al. · 2021 · Cell chemical biology
18. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
    Magda Bahcall, Mark Magdi Awad, Lynette Marie Sholl, Frederick Hugh Wilson, Man Xu, Stephen Wang, Sangeetha S. Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia Costanza Leonardi et al. · 2018 · Clinical Cancer Research
19. Translating insights into tumor evolution to clinical practice: promises and challenges
    Matthew W. Fittall, Peter Van Loo · 2019 · Genome Medicine
20. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
    July Katherine Rodríguez, Jenny Ávila, Christian Diego Rolfo, Alejandro Ruíz-Patiño, Alessandro Russo, Luisa Ricaurte, Camila Ordóñez‐Reyes, Oscar G. Arrieta, Zyanya Lucía Zatarain-Barrón, Gonzalo Recondo et al. · 2021 · Oncology and Therapy
21. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
    Yuebi Hu, Ryan S. Alden, Justin Iver Odegaard, Stephen R. Fairclough, Ruthia Chen, Jennifer C. Heng, Nora B. Feeney, Rebecca J. Nagy, Jayshree M Shah, Bryan C. Ulrich et al. · 2017 · Clinical Cancer Research
22. Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
    Sean Khozin, Chana Weinstock, Gideon Michael Blumenthal, Joyce Cheng, Kun He, Luning Zhuang, Hong Zhao, Rosane Charlab, Ingrid Fan, Patricia Keegan et al. · 2016 · Clinical Cancer Research
23. Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
    Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Duménil, Catherine Julié, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie C. Tisserand, Jean‐François Emile, Hélène Blons et al. · 2018 · OncoImmunology
24. Latest development of liquid biopsy
    Alvin H.K. Cheung, Chit Chow, Ka‐Fai To · 2018 · Journal of Thoracic Disease
25. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer
    Catherine W. Bennett, Guy Berchem, Yeoun Jin Kim, Victoria El‐Khoury · 2016 · Oncotarget
26. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
    Dana W.Y. Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, Oscar M. Rueda, Christopher G. Smith, Dineika Chandrananda, Ross Andrew Soo, Hong Liang Lim, Boon Cher Goh, Carlos Caldas et al. · 2018 · EMBO Molecular Medicine
27. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
    Wantao Wu, Yihan Liu, Shan Zeng, Ying Han, Hong Shen · 2021 · Journal of Hematology & Oncology
28. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
    Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, Elisabetta Zulato, Lorenzo Calvetti, Giulia Pasello, Valentina Guarneri, PierFranco Conte, Stefano Indraccolo · 2022 · British Journal of Cancer
29. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
    Jordi Remón, Benjamin Besse, Santiago Ponce-Aix, Ana Callejo, K. Al-Rabi, Reyes Bernabé, Laurent Greillier, Margarita Majem, Noemı́ Reguart, I. Monnet et al. · 2023 · Annals of Oncology
30. Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
    Marzia Del Re, Stefania Crucitta, Giulia Gianfilippo, Antonio Passaro, Iacopo Petrini, Giuliana Restante, Angela Michelucci, Stefano Fogli, Filippo de Marinis, Camillo Porta et al. · 2019 · International Journal of Molecular Sciences
31. Are liquid biopsies a surrogate for tissue EGFR testing?
    Jonathan Wade Goldman, Zorawar Singh Noor, Jordi Remón, Benjamin Besse, Nitzan Rosenfeld · 2017 · Annals of Oncology
32. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy
    Yuan Liang, Tiehua Zhang, Jie Zhang · 2020 · Pharmacological Research
33. Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer
    Bernard Pereira, Christopher T. Chen, Lipika Goyal, Charlotte S. Walmsley, Christopher J. Pinto, Islam Baiev, Read Allen, Laura E. Henderson, Supriya K. Saha, Stephanie Reyes et al. · 2021 · Nature Communications
34. Blood-based tumor biomarkers in lung cancer for detection and treatment
    Hirva Mansurali Mamdani, Shahid Sattar Ahmed, Samantha Ann Armstrong, Tony S.K. Mok, Shadia Ibrahim Jalal · 2017 · Translational Lung Cancer Research
35. Liquid biopsy tracking of lung tumor evolutions over time
    Alessandro Russo, Diego de Miguel‐Pérez, Muthukumar Gunasekaran, Katherine Ann Scilla, Rena S. Lapidus, Brandon Cooper, Ranee Mehra, Vincenzo Adamo, Umberto Malapelle, Christian Diego Rolfo · 2019 · Expert Review of Molecular Diagnostics
36. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
    Joshua Michael Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni Fontecedro, Christophe Dooms, Toshiaki Takahashi, Andrew W. Duda, Justin Iver Odegaard, Fernando Cruz‐Guilloty et al. · 2021 · Lung Cancer
37. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Antonio Passaro, Elena Guerini‐Rocco, Alessia Pochesci, Davide Vacirca, Gianluca Spitaleri, Chiara Catania, Alessandra Rappa, Massimo C.P. Barberis, Filippo de Marinis · 2017 · Pharmacological Research
38. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    Tri Le, David E. Gerber · 2019 · Cancers
39. Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
    Seung Tae Kim, Kimberly C. Banks, Se‐Hoon Lee, Kyung Kim, Joon Oh Park, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Richard Burnham Lanman et al. · 2017 · JCO Precision Oncology
40. Drug-biomarker co-development in oncology – 20 years and counting
    Julianne D. Twomey, Nina N. Brahme, Baolin Zhang · 2017 · Drug Resistance Updates
41. Molecular Pathology of Lung Cancer
    James Joseph Saller, Theresa A. Boyle · 2021 · Cold Spring Harbor Perspectives in Medicine
42. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples
    Broderick C. Corless, Gregory A. Chang, Samantha Cooper, Mahrukh M. Syeda, Yongzhao Shao, Iman Osman, George A. Karlin-Neumann, David Polsky · 2018 · Journal of Molecular Diagnostics
43. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Pekka Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun · 2020 · Lung Cancer
44. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
    Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel J. O’Neill, Aleksandra A. Markovets, Xiangning Huang, Juliann Chmielecki, Ryan James Hartmaier, Kenneth Stephen Thress, Paul D. Smith et al. · 2021 · Nature Communications
45. Liquid Biopsy: From Basic Research to Clinical Practice
    Mónica Macías, Estíbaliz Alegre, Ángel Díaz‐Lagares, Ana Patiño‐García, José Luis Perez‐Gracia, Miguel F. Sanmamed, Rafael López‐López, Nerea Varo, Álvaro González · 2017 · Advances in clinical chemistry
46. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer
    Geoffrey R. Oxnard, Cloud Peter Paweletz, Lynette Marie Sholl · 2016 · JAMA Oncology
47. Liquid Biopsy in Non-Small Cell Lung Cancer
    Miguel Ángel Molina‐Vila, Clara Mayo‐de‐las‐Casas, Ana A. Giménez-Capitán, Núria Jordana‐Ariza, Mónica Garzón, Ariadna Balada‐Bel, Sergi Villatoro, Cristina Teixidó, Beatriz García‐Peláez, Cristina Aguado et al. · 2016 · Frontiers in Medicine
48. The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
    Wen‐Zhao Zhong, Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2017 · Oncotarget
49. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
    Cheol‐Kyu Park, Hyun-Ju Cho, Yoo Duk Choi, In‐Jae Oh, Young‐Chul Kim · 2018 · Cancer Research and Treatment
50. Recent advances in liquid biopsy technologies for cancer biomarker detection
    Narshone Soda, Kimberley Clack, Muhammad J. A. Shiddiky · 2022 · Sensors & Diagnostics
51. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
    Elena Helman, Minh Nguyen, Chris Karlovich, Darrin Despain, A. Karin Choquette, Alexander I. Spira, Helena Alexandra Yu, D. Ross Camidge, Thomas C. Harding, Richard Burnham Lanman et al. · 2018 · Clinical Lung Cancer
52. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Reyes Bernabé, Nicholas Hickson, Andrew J. Wallace, Fiona Helen Blackhall · 2017 · European Journal of Cancer
53. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
    Tristan Alexandra Barnes, Grainne Mary O'Kane, Mark David Vincent, Natasha B. Leighl · 2017 · Frontiers in Oncology
54. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC
    Anna Buder, Maximilian Johannes Hochmair, Sophia Schwab, Tatjana Bundalo, Peter Schenk, Peter Errhalt, Romana E. Mikes, Gudrun Absenger, Kurt Patocka, Bernhard Baumgartner et al. · 2018 · Journal of Thoracic Oncology
55. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping
    Nicolas Marie Guibert, Hisashi Tsukada, David H. Hwang, Emily S. Chambers, Edmund S. Cibas, Tejus Bale, Julianna Supplee, Bryan C. Ulrich, Lynette Marie Sholl, Cloud Peter Paweletz et al. · 2018 · Lung Cancer
56. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
    Shumei Kato, Ryosuke Okamura, Manvita Mareboina, Suzanna Lee, Aaron Michael Goodman, Sandip Pravin Patel, Paul Timothy Fanta, Richard B. Schwab, Peter Vu, Victoria M. Raymond et al. · 2019 · JCO Precision Oncology
57. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
    Lin Li, Hui Wang, Chao Li, Zheng Wang, Ping Zhang, Yan Xu · 2017 · Oncotarget
58. Update on liquid biopsy in clinical management of non-small cell lung cancer
    Zhen Wu, Zhen Yang, Yu Dai, Qiang Zhu, Liang-An Chen · 2019 · OncoTargets and Therapy
59. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
    Matthew L. Hemming, Kelly S. Klega, Justin Rhoades, Gavin Ha, Kate E. Acker, Jessica L. Andersen, Edwin Thai, Anwesha Nag, Aaron R. Thorner, Chandrajit P. Raut et al. · 2019 · JCO Precision Oncology
60. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer
    Umberto Malapelle, Pasquale Pisapia, Alfredo Addeo, Oscar G. Arrieta, Beatríz Bellosillo, Andrés Felipe Cardona, Massimo Cristofanilli, Diego de Miguel‐Pérez, Valeria Cecilia Denninghoff, Ignacio Durán et al. · 2021 · Expert Review of Molecular Diagnostics
61. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma
    Joanna Przybył, Jacob J. Chabon, Lien Spans, Kristen Nooshin Ganjoo, Sujay Vennam, Aaron M. Newman, Erna Forgó, Sushama Varma, Shirley Zhu, Maria Dêbiec‐Rychter et al. · 2018 · Clinical Cancer Research
62. Liquid biopsy genotyping in lung cancer: ready for clinical utility?
    Wei-Lun Huang, Yi-Lin Chen, Szu‐Chun Yang, Chung‐Liang Ho, Fang Wei, David T. Wong, Wu‐Chou Su, Chien‐Chung Lin · 2017 · Oncotarget
63. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
    Takashi Seto, Naoyuki Nogami, Nobuyuki Yamamoto, Shinji Atagi, Naoki Tashiro, Yoko Yoshimura, Yutaka Yabuki, Hideo Saka · 2018 · Oncology and Therapy
64. Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine
    Oluwaseun Adebayo Bamodu, Chen‐Chih Chung, Thomas R. Pisanic · 2023 · The Journal of Liquid Biopsy
65. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
    Judith N. Müller, Markus Falk, Jatin Talwar, Nicole Neemann, Erika Mariotti, Miriam Bertrand, Tobias Zacherle, Sotirios Lakis, Roopika Menon, Christian Gloeckner et al. · 2017 · Journal of Thoracic Oncology
66. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients
    Gahee Park, Joo Kyung Park, Dae‐Soon Son, Seung‐Ho Shin, Yeon Jeong Kim, Hyo-Jeong Jeon, Jae Lee, Woong‐Yang Park, Kwang Hyuck Lee, Donghyun Park · 2018 · Scientific Reports
67. Scientific Advances in Thoracic Oncology 2016
    Ross Andrew Soo, Emily C.A. Stone, K. Michael Cummings, James R. Jett, John K. Field, Harry J.M. Groen, James L. Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Đačić et al. · 2017 · Journal of Thoracic Oncology
68. Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
    Anna Sophie Berghoff, Beatríz Bellosillo, Christophe Caux, Adrianus Johannes De Langen, Julien Mazières, Nicola Normanno, Matthias Preusser, Mariano Provencio, Federico Rojo, Jürgen Wolf et al. · 2019 · ESMO Open
69. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
    Yang Liu, Li Sun, Zhicheng Xiong, Xin Sun, Shuling Zhang, Jie‐Tao Ma, Cheng‐Bo Han · 2017 · OncoTargets and Therapy
70. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers
    Olatunji Boladale Alese, Natalie Cook, Ana Ortega Franco, Mark Bilinyi Ulanja, Lavinia Tan, Jeanne Tie · 2022 · American Society of Clinical Oncology Educational Book
71. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
    Carmelo Laface, Felicia Maria Maselli, Anna Natalizia Santoro, Maria Laura Iaia, Francesca Ambrogio, Marigia Laterza, Chiara Guarini, Pierluigi De Santis, Martina Perrone, Palma Fedele · 2023 · Pharmaceutics
72. Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
    Elisa Roca, Marta Pozzari, William Vermi, Valeria Tovazzi, Alice Baggi, Vito Amoroso, Daniela Nonnis, Salvatore Intagliata, Alfredo Berruti · 2018 · Lung Cancer
73. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
    César Serrano, Ana P. Vivancos, Antonio Lopez Pousa, Judit Matito, Francesco Mattia Mancuso, Claudia María Valverde, Sergi Quiroga, Stefania Landolfi, Sandra Castro, Cristina Dopazo et al. · 2020 · BMC Cancer
74. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
    Manuel Caitano Maia, Meghan M. Salgia, Sumanta Kumar Pal · 2020 · Nature Reviews Urology
75. The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy
    Tejas Shegekar, Sahitya Vodithala, Anup Juganavar · 2023 · Cureus
76. Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Yvette N. Lamb, Lesley J. Scott · 2017 · Targeted Oncology
77. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
    written on behalf of the AME Lung Cancer Collaborative Group, Tao Jiang, Chunxia Su, Shengxiang Ren, Federico Cappuzzo, Gaetano Rocco, Joshua David Palmer, Nico van Zandwijk, Fiona Helen Blackhall, Xiuning Le et al. · 2018 · Journal of Thoracic Disease
78. Cell-free DNA in cancer: current insights
    Heidi Fettke, Edmond M. Kwan, Arun Azad · 2018 · Cellular Oncology
79. Circulating tumor DNA analysis in the era of precision oncology
    Rabih Said, Nicolas Marie Guibert, Geoffrey R. Oxnard, Apostolia Maria Tsimberidou · 2020 · Oncotarget
80. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
    Saya Liz Jacob, Andrew A. Davis, Lorenzo Gerratana, Marko Velimirovic, Ami N. Shah, Firas Wehbe, Neelima Katam, Qiang Zhang, Lisa Flaum, Kalliopi P. Siziopikou et al. · 2021 · Clinical Cancer Research
81. Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
    Nobuhiko Hasegawa, Shinji Kohsaka, Kana Kurokawa, Yuki Shinno, Ikuko Takeda Nakamura, Toshihide Ueno, Shinya Kojima, Masahito Kawazu, Yoshiyuki Suehara, Muneaki Ishijima et al. · 2021 · Cancer Science
82. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
    Paola Bordi, Marzia Del Re, Roberta Minari, Eleonora Rofi, Sebastiano Buti, Giuliana Restante, Anna Squadrilli, Stefania Crucitta, Chiara Casartelli, Letizia Gnetti et al. · 2019 · Lung Cancer
83. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies
    Clemens Grassberger, David M. McClatchy, Changran Geng, Sophia C. Kamran, Florian Johannes Fintelmann, Yosef E. Maruvka, Zofia Piotrowska, Henning Willers, Lecia Van Dam Sequist, Aaron N. Hata et al. · 2019 · Cancer Research
84. Genetic profiling of cancer with circulating tumor DNA analysis
    Ling Lu, Junqin Bi, Liming Bao · 2018 · Journal of genetics and genomics/Journal of Genetics and Genomics
85. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
    Ryo Ariyasu, Shingo Nishikawa, Ken Uchibori, Tomoko Oh‐hara, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Satoru Kitazono et al. · 2018 · Lung Cancer
86. Liquid Biopsy in Tumor Genetic Diagnosis
    Andreas Jung, Thomas Kirchner · 2018 · Deutsches Ärzteblatt international
87. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
    Bin-Chi Liao, Chia‐Chi Lin, Jih‐Hsiang Lee, James Chih‐Hsin Yang · 2016 · Journal of Biomedical Science
88. Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma
    Álvaro Taus, Laura Camacho, Pedro Rocha, Max Hardy-Werbin, Lara Pijuán, Gabriel Piquer, Eva López, Alba Dalmases, Raquel Longarón, Sergi Clavé et al. · 2018 · Clinical Lung Cancer
89. Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
    Jennifer Wilkinson Carlisle, Suresh S. Ramalingam · 2019 · Future Oncology
90. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
    Kang-Kook Lee, Youjin Kim, Hyun Ae Jung, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Yoon‐La Choi, Jong‐Mu Sun · 2019 · Lung Cancer
91. Progress in the Management of Advanced Thoracic Malignancies in 2017
    Roberto Ferrara, Laura Mezquita, Benjamin Besse · 2018 · Journal of Thoracic Oncology
92. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Yasuhiro X. Kato, Yukio Hosomi, Kageaki Watanabe, Makiko Yomota, Shoko Kawai, Yusuke Okuma, Kaoru Kubota, Masahiro Seike, Akihiko Gemma, Tatsuru Okamura · 2019 · Journal of Thoracic Disease
93. The Role of Cell-Free DNA in Cancer Treatment Decision Making
    András Telekes, Anna Horváth · 2022 · Cancers
94. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer
    Takahisa Kawamura, Hirotsugu Kenmotsu, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Katsuhiro Omae, Keita P. Mori et al. · 2017 · Clinical Lung Cancer
95. Liquid biopsy for pediatric central nervous system tumors
    Erin R. Bonner, Miriam Bornhorst, Roger J. Packer, Javad Nazarian · 2018 · npj Precision Oncology
96. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer
    Yasuhiro Koh, Satomi Yagi, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi et al. · 2019 · Clinical Lung Cancer
97. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
    Luigi Pasini, Paola Ulivi · 2019 · Journal of Clinical Medicine
98. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer
    Sandra Ortiz‐Cuaran, Laura Mezquita, Aurélie Swalduz, Mihaela D. Aldea, Julien Mazières, Camille Léonce, Cécile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores et al. · 2020 · Clinical Cancer Research
99. Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
    Bin-Chi Liao, Chia‐Chi Lin, Jih‐Hsiang Lee, James Chih‐Hsin Yang · 2017 · Lung Cancer
100. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer
     Rui Wan, Zhijie Wang, J. Jack Lee, Shuhang Wang, Qingqing Li, Fuchou Tang, Jin Wang, Yu Ling Sun, Hua Bai, Di Wang et al. · 2017 · Journal of Thoracic Oncology